跳至主要内容
临床试验/NCT03366818
NCT03366818已完成不适用

Efficacy and Safety of VERSI System for Acute Ischemic Stroke

Kobe City General Hospital1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2017年9月21日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10
试验地点
1
主要终点
incidence of treatment-related severe adverse event

研究概览

简要总结

To confirm efficacy and safety of VERSI system for acute ischemic stroke

详细描述

Efficacy; TICI 2a or more recanalization upto 3 pass of study device Safety; symptomatic intracranial hemorrhage within 24 hours of procedure

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • onset to treat within 8 hours
  • NIHSS 8 or more
  • ASPECTS 5 or more
  • Target vessel is ICA, MCA, VA, BA, PCA
  • non-eligible or failed IV rt-PA

排除标准

  • known hemorrhagic tendency
  • arterial dissection, vasculitis
  • allergy for contrast media
  • other inappropriate condition

研究组 & 干预措施

thrombectomy

Experimental

thrombectomy by Versi system

干预措施: thrombectomy (Device)

结局指标

主要结局

incidence of treatment-related severe adverse event

时间窗: within 24 hours after procedure

symptomatic intracranial hemorrhage

次要结局

  • all intracralnial hemorrhage(within 24 hours after procedure)
  • Severe adverse event related to device(within 24 hours after procedure)
  • recanalization ability of device(immediatry after procedure)
  • recovery to independent life {modified Rankin score of 2 or less](90days after procedure)
  • acceptable clinical outcome(90days after procedure)

研究者

发起方
Kobe City General Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Nobuyuki Sakai

Director, Neurosurgery

Kobe City General Hospital

研究点 (1)

Loading locations...

相似试验